<SEC-DOCUMENT>0001062993-17-000814.txt : 20170214
<SEC-HEADER>0001062993-17-000814.hdr.sgml : 20170214
<ACCEPTANCE-DATETIME>20170213173133
ACCESSION NUMBER:		0001062993-17-000814
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170208
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170214
DATE AS OF CHANGE:		20170213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		17600985

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp.: Form 8-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT><BR></B><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT><BR>Washington, D.C. 20549
</B></P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT <BR></B>Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B>February 8,
2017 </B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.
</FONT></U><BR>
</B>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><U><B>Nevada </B></U></TD>
    <TD align=center width="33%"><U><B>000-52138 </B></U></TD>
    <TD align=center width="33%"><U><B>20-2000871 </B></U></TD></TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
    <TD align=center width="33%">(IRS Employer </TD></TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=left width="33%">&nbsp; </TD>
    <TD align=center width="33%">Identification No.) </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><U><B>156 Valleyview Road, Kelowna, BC Canada </B></U></TD>
    <TD align=center width="50%"><U><B>V1X 3M4 </B></U></TD></TR>
  <TR vAlign=top>
    <TD align=center>(Address of principal executive offices) </TD>
    <TD align=center width="50%">(Zip Code) </TD></TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code <B><u>(250)
765-6424 </u></B></P>
<P align=center><B><U>N/A </U><BR></B>(Former name or former address, if changed
since last report.) </P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions: </P>
<P align=justify>[&nbsp; ]&nbsp; Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425) </P>
<P align=justify>[&nbsp; ]&nbsp; Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a -12) </P>
<P align=justify>[&nbsp; ]&nbsp; Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) </P>
<P align=justify>[&nbsp; ]&nbsp; Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>Item 7.01 </B></TD>
    <TD align=left width="90%"><B>Regulation FD Disclosure
</B></TD></TR></TABLE>
<P align=justify>A copy of the news release announcing that through its wholly
owned Canadian subsidiary Lexaria Canpharm Corp., has signed and entered a
master collaborative research agreement with the <U>National </U><U>Research
Council of Canada</U><U> </U>(NRC) is filed as exhibit 99.1 to this current
report and is hereby incorporated by reference. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>Item 9.01 </B></TD>
    <TD align=left width="90%"><B>Financial Statements and Exhibits
  </B></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="exhibit99-1.htm">99.1</a> </TD>
    <TD align=left width="90%" bgColor=#eeeeee><a href="exhibit99-1.htm">Press Release dated February 8,
      2017</a> </TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify><B>LEXARIA BIOSCIENCE CORP. </B></P>
<P align=justify><I><U>/s/ Chris
Bunka&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U><BR></I><B>Chris Bunka <BR></B>CEO, Principal Executive Officer </P>
<P align=justify>Date: February 8, 2017</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp.: Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_1></A>
<P align=right><B>Exhibit 99.1 </B></P>
<P align=center><B><font size="4">Lexaria Signs Master Collaborative Research Agreement</font></B></P>
<P align=justify>Kelowna, BC / February 8, 2017 / Lexaria Bioscience Corp.
(OTCQB:LXRP) (CSE:LXX) (&#147;the Company&#148; or &#147;Lexaria&#148;), through its wholly owned
Canadian subsidiary Lexaria Canpharm Corp., has signed and entered a master
collaborative research agreement with the <U>National Research</U> <U>Council of
Canada</U><U> </U>(NRC) to investigate technical aspects and new opportunities
associated with bioavailability enhancement of lipophilic active ingredient
compositions. </P>
<P align=justify>Lexaria believes that results from this scientific
collaboration could motivate license adoption of Lexaria&#146;s patented flavour
masking and nutrient delivery enhancement technology, including but not limited
to the vitamin, pain reliever and nicotine sectors. Lexaria&#146;s technology is
patented in the US, and patent pending in Canada and in 41 other countries
around the world. </P>
<P align=justify>Under the agreement, Lexaria and the National Research Council
will both provide up to CDN$125,000 in funding for this research, a total
investment of up to $250,000. The master research agreement has an 18-month
term, during which a number of shorter-term studies will be undertaken. The
collaboration will investigate and define the chemical nature of the molecular
association that Lexaria`s patented technology is believed to effectuate between
lipophilic active agents and fatty acids as solubility and bioavailability
enhancing agents. Effective delivery of lipophilic active agents spans across
industry sectors such as, food, vitamins, pharmacy and more, which are
multi-billion dollar opportunities. </P>
<P align=justify>Prospective lipophilic active agents to be investigated under
the research agreement include cannabinoids (e.g., cananbidiol &#147;CBD&#148; and
tetrahydrocannabinol &#147;THC&#148;), fat soluble vitamins, non-steroidal
anti-inflammatory drugs (&#147;NSAIDs&#148;) and nicotine, as described in Lexaria`s
issued and pending patent applications as well as potentially other high value
bioactives to be determined. The research agreement also provides for possible
licensing of any arising, non-competing Lexaria intellectual property to NRC or
its sub-licensees on terms to be defined in the future as applicable.</P>
<P align=justify>&#147;This co-funded research agreement with the National Research
Council of Canada is a major achievement for us,&#148; said John Docherty, President
of Lexaria Bioscience Corp. &#147;Having the privilege to work within their high
caliber facilities alongside their expert scientists will allow Lexaria to
further advance the characterization and commercial potential of its technology
in the fastest way possible for a company of our size. Furthermore, the fact
that they have a Level 2 dealer`s licensed facility in Canada in which some of
this work can be conducted is of particular importance, thereby allowing us to
advance research on controlled substances with ease.&#148; </P>
<P align=justify>&#147;The National Research Council&#146;s support in the development and
commercialization of our technology is highly validating for our Company&#148;, said
Chris Bunka, CEO of Lexaria Bioscience Corp. &#147;Positive findings from this joint
investigation will be of tremendous value to Lexaria in order to broaden the
scientific understanding of our intellectual property suite and support our
abilities to attract additional strategic licensees across the greater
therapeutic foods, dietary supplements and pharmaceutical sectors.&#148;</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify>Lexaria intends to commercialize its technology for widespread
use by markets throughout the world, including over the counter pain remedy
sector, vitamins and food supplements, and even the nicotine industries and
more. To achieve that, this undertaking of fundamental research will enhance the
Company&#146;s ability to enter into these distinct market sectors. </P>
<P align=justify>Additional information will be released regarding completion of
the joint research initiatives to be conducted under this research agreement as
they are confirmed and available.</P>
<P align=justify>About Lexaria </P>
<P align=justify>Lexaria Bioscience Corp. is a food biosciences company with a
proprietary technology for improved delivery of bioactive compounds. The
Company&#146;s lipophilic enhancement technology has been shown to enhance the
bioavailability of orally ingested cannabinoids, while also masking taste. This
technology promotes healthy ingestion methods, lower overall dosing and higher
effectiveness in active molecule delivery. The Company&#146;s technology is
patent-protected for cannabidiol (CBD) and all other non-psychoactive
cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other
psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs),
nicotine and other molecules. <U>www.lexariabioscience.com</U> </P>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT: <BR>Lexaria Bioscience
Corp.<BR>Chris Bunka <BR>Chairman &amp; CEO <BR>(250) 765-6424 </P>
<P align=justify>FORWARD-LOOKING STATEMENTS </P>
<P align=justify>This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements. Such forward-looking statements are
estimates reflecting the Company's best judgment based upon current information
and involve a number of risks and uncertainties, and there can be no assurance
that other factors will not affect the accuracy of such forward-looking
statements. Access to capital, or lack thereof, is a major risk and there is no
assurance that the Company will be able to raise required working capital.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation,
managing and maintaining growth, the effect of adverse publicity, litigation,
competition, the patent application and approval process and other factors which
may be identified from time to time in the Company's public announcements and
filings. There is no assurance that the master collaborative research agreement
with the National Research Council of Canada will provide any benefit to
Lexaria, or that the Company will experience any growth through participation in
these sectors or as a result of the agreement. There is no assurance that
existing capital is sufficient for the Company's needs or that it will be able
to raise additional capital. There is no assurance that Lexaria will
successfully complete any other contemplated or existing technology license
agreements, nor that Lexaria&#146;s technology will deliver any improvement in taste
or bioavailability with any reliability nor across any product category. There
is no assurance that any planned corporate activity, business venture, or
initiative will be pursued, or if pursued, will be successful. There is no
assurance that any hemp oil or cannabinoid-based product will promote, assist,
or maintain any beneficial human health conditions whatsoever, nor that any
patent application in the USA or any other nation or under any treaty will
result in the award of an actual patent; nor that an award of any actual patent
will protect against challenges from unknown third parties. There is no
assurance that any of Lexaria&#146;s postulated uses, benefits, or advantages for the
patent-pending technology will in fact be realized in any manner or in any part.
No statement herein has been evaluated by the Food and Drug Administration
(FDA). ViPova<SUP>TM</SUP> products are not intended to diagnose, treat, cure or
prevent any disease.</P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
